Extracellular vesicles derived from astrocyte-treated with haFGF14-154 attenuate Alzheimer phenotype in AD mice.

doi:10.7150/thno.70951

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Extracellular vesicles derived from astrocyte-treated with haFGF14-154 attenuate Alzheimer phenotype in AD mice.

Theranostics - 1 Jan 2022

Peng Dong, Wang Youjin, Xiao Yuanjie, Peng Mengyuan, Mai Wanwen, Hu Bo, Jia Yanbin, Chen Hongxia, Yang Yan, Xiang Qi, Su Zhijian, Zhang Qihao, Huang Yadong

Abstract excerpt

Background: aFGF content in serum and cerebrospinal fluid is increased in Alzheimer's disease (AD) patients and attenuates the activation of astrocytes. Extracellular vesicles (EVs) are a major mediator in astrocyte-neuron communications. Since excessive or persistent reactive astrocytes lead to chronic inflammation and neuronal dysfunction, and the activation of astrocytes can be inhibited by aFGF, we proposed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer Disease
Share to Amyloid beta-Peptides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytes

Share to Brain-Derived Neurotrophic Factor

Share to Extracellular Vesicles

Share to Mice

Share to Mice, Transgenic

Share to MicroRNAs

Source

Open in PubMed Open full text

Identifiers

PMID: 35664060
DOI: 10.7150/thno.70951
PMCID: PMC9131260

Provenance

PubMed metadata and Literature Corpus relationships.